At Hikma, we want to be a part of the solution to drug shortages that impact patient care.
In the last three years, we have launched almost 20 products into shortage situations. Recently, after some significant supply disruptions for injectable opioid medicines, Hikma was able to increase our capacity to address the shortage of critical products like hydromorphone and morphine. As a result, doctors and hospitals were able to perform important patient surgeries without delay.
To assure we are a meaningful part of the solution to drug shortages, we will continue making significant investments when needed—including adding production lines, going to 24/7 manufacturing and hiring additional staff. We will also continue working closely with the FDA and other policymakers in our efforts to better respond to and prevent shortages of vital medicines.